Omega Therapeutics Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ Omega Therapeutics, Inc. (Nasdaq: OMGA) ( Omega ), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines, today announced the pricing of its initial public offering of 7,400,000 shares of its common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Omega. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $125.8 million, excluding any exercise of the underwriters option to purchase additional shares. Omega s common stock is expected to begin trading on the Nasdaq
New-york
United-states
Cambridge
Cambridgeshire
United-kingdom
David-rosen
Wedbush-pacgrow
Joseph-rayne
Piper-sandler
Exchange-commission
Prospectus-department
Equity-syndicate-prospectus-department